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Health-related quality of life (HRQL) measures
extend patient outcome assessment beyond sur-
vival, adverse effects, and clinical efﬁcacy, and
reﬂect the patient’s perspective on the impact of
disease and its treatment on functioning and well-
being. An important objective for evaluating HRQL
outcomes is to demonstrate the value of new phar-
maceutical treatments relative to other competing
treatments. The pharmaceutical industry’s intent in
supporting clinical trials with HRQL measures is to
achieve labeling and/or promotional claims for mar-
keting to physicians, pharmacists, health-care deci-
sion makers, and patients [1,2].
Morris and Miller [3] provide an informative and
useful policy analysis of the evidence required for
HRQL and other patient-reported outcome (PRO)
claims for labeling or promotion. They argue that
there is apparent inconsistency in the standards of
evidence used that depends on whether the HRQL
ﬁndings appear in the product label, and where on
the label they appear. The result is that there is evi-
dence that promotional claims for HRQL and other
PRO effects require higher standards of evidence if
no HRQL information is included in the product
label. These authors further recommend that the
level of substantiating evidence for an HRQL or
PRO claim for advertising should be based on
where in the product label this information would
be placed. In most cases, HRQL ﬁndings would be
included in the Clinical Studies section of the label
and would therefore require evidence from at least
one well-controlled and scientiﬁcally adequate 
clinical trial.
Over the past 10 years, there has been some
inconsistency within the FDA, leading to confusion
among HRQL researchers, industry personnel, and
clinicians in terms of the standards required to
support promotional or labeling claims of HRQL
effects. Clearly, a regulatory guideline for the place-
ment of HRQL and PRO ﬁndings in product labels
and the expected substantiating evidence for HRQL
and PRO claims would assist FDA reviewers and
the pharmaceutical industry. It is unlikely that the
FDA will issue guidance on HRQL labeling and
promotional claims in the near future. However,
FDA reviewers and advisory committees are evolv-
ing in their understanding of HRQL and patient
outcome assessment, and there is an increasing level
of consistency in the FDA’s decision making regard-
ing HRQL promotional and labeling claims. From
the perspective of the FDA, the HRQL and other
PROs assessed in pivotal clinical trials and new
drug applications add to the understanding of 
the effectiveness of new treatments. Consequently,
PROs are treated as clinical efﬁcacy end points, and
substantial evidence is needed to support an HRQL
labeling or promotional claim.
There is a need for consistent standards of 
evidence to support labeling and/or promotional
claims of HRQL beneﬁts associated with a phar-
maceutical product. This evidence needs to be based
on state-of-the-art HRQL research, but what
amount of evidence is sufﬁcient for labeling vs. pro-
motional claims? Are the results from one adequate
and well-controlled clinical trial sufﬁcient for sub-
stantiating an HRQL or PRO claim for advertising
purposes? The article by Morris and Miller [3] pro-
vides an informative starting point for discussing
relevant evidentiary standards, whether based on
the FDA’s current standards or the Federal Trade
Commission’s (FTC) competent and reliable stan-
dards, for evaluation of HRQL and PRO claims.
Statements pertaining to HRQL effects must be
supported by well-controlled clinical trials, psycho-
metrically sound instruments, and adequate statis-
tical methods [1,2]. In many cases, a single clinical
trial with an adequate research design, sufﬁcient
sample size and power, attention to HRQL instru-
ment selection and data collection procedures, and
appropriate statistical analysis would be sufﬁcient
to provide useful information on HRQL outcomes.
The challenge for both industry researchers and
regulatory agency reviewers is to reach a consensus
on the standards for scientiﬁc evidence required to
support HRQL and PRO claims for labeling and
advertising. Regulatory agencies need consistent
standards for labeling and advertising claims. These
standards must be based on consensus within the
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HRQL scientiﬁc community in terms of state-of-
the-art research methods, instrumentation and
assessment procedures, and the ﬂexibility to accom-
modate new measurement research and method-
ologies. The communication of patient-reported
health outcomes must be clear, unambiguous, and
based on adequate scientiﬁc methods. In this way,
physicians, patients, and health-care decision
makers will have conﬁdence in information about
the impact of treatment on patient functioning and
well being.
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